<DOC>
	<DOC>NCT00812058</DOC>
	<brief_summary>The purpose of this study is to test a new drug, RG2417, to see how the drug affects symptoms of bipolar I depression and to make sure it is safe in humans.</brief_summary>
	<brief_title>A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<criteria>Bipolar I Disorder, most recent episode depressed History of 2 or more manic or mixed episodes, at least one of which required pharmacologic treatment for manic symptoms Current manic, hypomanic or mixed episode Rapid cycling bipolar disorder (4 or more mood episodes in the last year) Dementia or any other Axis I diagnosis (besides bipolar I) that requires treatment Alcohol or drug dependence within 6 months; alcohol or drug abuse within 3 months Positive urine drug test for amphetamines, cocaine metabolites, opiates and/or phencyclidine(PCP) Axis II diagnosis likely to interfere with study compliance Serious suicidal or homicidal risk Sensitivity to any of the drug ingredients, including lactose Women who are pregnant, breast feeding or refuse to use adequate birth control Current seizure disorder Current episode of depression is longer than 1 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Bipolar Depression</keyword>
	<keyword>Bipolar Disease</keyword>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Bipolar</keyword>
	<keyword>Manic Depression</keyword>
	<keyword>Manic Depressive Disorder</keyword>
</DOC>